Madrigal Pharmaceuticals has entered an exclusive global licensing agreement with CSPC Pharmaceutical Group for SYH-2086, a preclinical oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. Madrigal paid $120 million upfront with potential milestone payments exceeding $2 billion. The company plans to combine SYH-2086 with its existing NASH drug Rezdiffra to address fatty liver disease, aiming for first-in-human trials in the first half of 2026. This deal expands Madrigal’s portfolio in metabolic disease therapeutics and underlines its strategic commitment to combination approaches.